Implication of Critical Pharmacokinetic Gene Variants on Therapeutic Response to Metformin in Type 2

Authors:

Abstract
Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.
Funding Information
  • Indian Council of Medical Research
  • Technology Information Forecasting and Assessment Council-Centre of Relevance and Excellence (EMR/2015/002384)
  • Dr TMA Pai Endowment Chair in Pharmacogenomics
  • Manipal Academy of Higher Education

This publication has 23 references indexed in Scilit: